Palitin Techonicials Bremalanotideは,糖尿病の腎臓疾患を治療し,株を増幅することを約束している. Palatin Technologies' Bremelanotide shows promise in treating diabetic kidney disease, boosting stock.

慢性腎臓病の主な原因である2型糖尿病性腎不全の治療におけるブレメラノチドの第IIb期試験の結果が陽性であることを報告した. Palatin Technologies reported positive Phase IIb trial results for Bremelanotide in treating Type 2 diabetic nephropathy, a leading cause of chronic kidney disease. 尿中のタンパク質は30%減少し,腎臓機能は71%改善した. The study showed 71% of patients achieved a 30% reduction in protein in urine and 71% had improved kidney function. 会社の株は4.37%から78ドルまで上昇し,その成果は陽性だった. The company's stock rose 4.37% to $0.78 on the positive results.